Cryptococcus infection medical therapy

Cryptococcus infection Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cryptococcus infection from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cryptococcus infection medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cryptococcus infection medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cryptococcus infection medical therapy
CDC on Cryptococcus infection medical therapy
Cryptococcus infection medical therapy in the news
Blogs on Cryptococcus infection medical therapy
Directions to Hospitals Treating Type chapter name here
Risk calculators and risk factors for Cryptococcus infection medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Medical Therapy

Antimicrobial Regimen

• Cryptococcus Meningoencephalitis in Human Immunodeficiency Virus–Infected Individuals
  • Induction Therapy

• Preferred regimen (1): Amphotericin B deoxycholate (0.7–1.0 mg/kg per day) plus flucytosine (100 mg/kg per day) for 2 weeks Template:AND Begin HAART 2–10 weeks after the start of initial antifungal treatment.
• Preferred regimen (2): Liposomal AmB (3–4 mg/kg per day) or ABLC (5 mg/kg per day, with renal function concerns) plus flucytosine (100 mg/kg per day) for 2 weeks Template:AND Begin HAART 2–10 weeks after the start of initial antifungal treatment.
• Preferred regimen (3): AmBd (0.7–1.0 mg/kg per day) or liposomal AmB (3–4 mg/kg per day) or ABLC (5 mg/kg per day, for flucytosine-intolerant patients)